Biotech Executes 1-for-150 Reverse Split, Advances Key Ophthalmology Drug to Human Trials
summarizeSummary
Curative Biotechnology announced a 1-for-150 reverse stock split, effective March 23, 2026, which will reduce outstanding shares from approximately 1.02 billion to 6.8 million. This significant capital restructuring is a strategic step towards uplisting to the OTCQB Venture Market, aiming for improved capital structure and broader investor awareness. Concurrently, the company has made substantial progress in its metformin-based ophthalmology platform, securing a manufacturing proposal for sterile ophthalmic drops. This manufacturing capability will support a planned Phase 1 human clinical study at the National Institutes of Health (NIH) for dry Age-Related Macular Degeneration (AMD), as well as an initial K9 study for PDE6-associated retinal degeneration. For a development-stage biotech, advancing a drug into human clinical trials and securing manufacturing are critical milestones that significantly de-risk the pipeline and validate its potential. Investors should monitor the anticipated manufacturing start in mid-April 2026, the formal OTCQB uplisting application, and the initiation and progress of the planned clinical studies.
At the time of this announcement, CUBTD was trading at $153.00 on OTC in the Life Sciences sector. The 52-week trading range was $67.50 to $348.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.